Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Angiogenex Inc    AGGX

ANGIOGENEX INC (AGGX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCompany 
Quotes 5-day view   Delayed Quote. Delayed Otc Bulletin Board - Othe…
11/29/2017 11/30/2017 12/15/2017 01/03/2018 01/24/2018 Date
0.28(c) 0(c) 0.4(c) 0.2(c) 0.202(c) Last
161 2 82 500 182 1 000 Volume
-37.78% -100.00% -50.00% +1.00% Change
More quotes
Company
AngioGenex, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel platform of anti-proliferative drugs for the treatment of cancer and macular degeneration.The company was founded by Michael M. Strage on March 31, 1999 and is headquartered in New York, NY. 
More about the company
Latest news on ANGIOGENEX INC
2017ANGIOGENEX INC : Michael Aronstein to Head AngioGenex, Inc. Board of Directors
AC
2017ANGIOGENEX, INC. : Change in Directors or Principal Officers, Regulation FD Disc..
AQ
2017ANGIOGENEX : Management's Discussion and Analysis of Financial Condition and Res..
AQ
2017ANGIOGENEX, INC. : Financial Statements and Exhibits (form 8-K)
AQ
2008ANGIOGENEX INC COM USD0.001 : AngioGenex Reviews 2008 Achievements and Sets Goal..
PR
2008ANGIOGENEX INC COM USD0.001 : AngioGenex Appoints New CEO to Direct Development ..
PR
More news
Sector news : Biotechnology & Medical Research - NEC
02/22SANGAMO THERAPEUTICS : Surges on Therapy Collaboration Deal with Kite -- Market ..
DJ
02/22Sangamo in $3 billion gene-editing deal with Gilead
RE
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
More sector news : Biotechnology & Medical Research - NEC
Chart ANGIOGENEX INC
Duration : Period :
Angiogenex Inc Technical Analysis Chart | AGGX | US03475U3014 | 4-Traders
Managers
NameTitle
Robert Benezra President, Chief Executive Officer & Director
Michael Charles Aronstein Non-Executive Chairman
Michael M. Strage Chief Operations Officer, Director & VP
Martin F. Murray Chief Financial Officer & Director
Sector and Competitors
1st jan.Capitalization (M$)
ANGIOGENEX INC-49.50%0
CELLTRION, INC.--.--%34 853
IQVIA HOLDINGS INC2.41%20 749
LONZA GROUP-6.57%19 479
INCYTE CORPORATION-9.71%17 877
NEKTAR THERAPEUTICS39.74%13 613